Matrix metalloproteinase 2 and tissue inhibitor of matrix metalloproteinases 2 in the diagnosis of colorectal adenoma and cancer patients

Folia Histochemica et Cytobiologica

Volumn 48, Issue 4, 2010, Pages 564-571

  Groblewska, Magdalena ^a   Mroczko, Barbara ^a   Gryko, Mariusz ^a   Kedra, Bogusław ^a   Szmitkowski, Maciej ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Colorectal adenoma; Colorectal cancer; Matrix metalloproteinase 2; Tissue inhibitor of matrix metalloproteinases 2

Indexed keywords

CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; GELATINASE A; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; COLORECTAL ADENOMA; COLORECTAL CANCER; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISEASE MARKER; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROPARTICLE ENZYME IMMUNOASSAY; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY ANALYSIS; TUMOR DIFFERENTIATION;

EID: 79958069087     PISSN: 02398508     EISSN: 18975631     Source Type: Journal    
DOI: 10.2478/v10042-010-0076-1     Document Type: Article

References (29)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225-49.
2. Fearon ER Molecular genetics of colorectal cancer. Ann NY Acad Sci. 1995;768:101-10.
3. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990; 61:759-67.
4. Vihinen P, Kahari VM. Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int J Cancer. 2002;99:157-66.
5. Garg P, Sarma D, Jeppsson S, Patel NR, Gewirtz AT, Merlin D, et al. Matrix metalloproteinase-9 functions as a tumor suppressor in colitis-associated cancer. Cancer Res. 2010;70:792-801.
6. Herszényi L, Sipos F, Galamb O, et al. Matrix metalloproteinase-9 expression in the normal mucosa-adenoma-dysplasia- adenocarcinoma sequence of the colon. Pathol Oncol Res. 2008;14:31-7.
7. Talvensaari-Mattila A, Paakko P, Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 (MMP-2) is associated with survival in breast carcinoma. Br J Cancer. 2003;89:1270-75.
8. Kubben FJ, Sier CF, Meijer MJ, et al. Clinical impact of MMP and TIMP gene polymorphisms in gastric cancer. Br J Cancer. 2006;95:744-51.
9. Giannopoulos G, Pavlakis K, Parasi A, et al. The expression of matrix metalloproteinases-2 and -9 and their tissue inhibitor 2 in pancreatic ductal and ampullary carcinoma and their relation to angiogenesis and clinicopathological parameters. Anticancer Res. 2008;28:1875-81.
10. Murnane MJ, Cai J, Shuja S, McAneny D, Klepeis V, Willett JB. Active MMP-2 effectively identifies the presence of colorectal cancer. Int J Cancer. 2009;125:2893-902.
11. Oshima T, Kunisaki C, Yoshihara K, et al. Clinicopathological significance of the gene expression of matrix metalloproteinases and reversion-inducing cysteine-rich protein with Kazal motifs in patients with colorectal cancer: MMP-2 gene expression is a useful predictor of liver metastasis from colorectal cancer. Oncol Rep. 2008;19:1285-91.
12. Waas ET, Wobbes T, Ruers T, Lomme RM, Hendriks T. Circulating gelatinases and tissue inhibitor of metalloproteinase-1 in colorectal cancer metastatic liver disease. Eur J Surg Oncol. 2006;32:756-63.
13. Wu W, He JT, Ruan JD, Wang RB, Zhang YD. Expression of MMP-2, MMP-9 and collagen type IV and their relationship in colorectal carcinomas. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2008;24:908-9.
14. Li BH, Zhao P, Liu SZ, Yu YM, Han M, Wen JK. Matrix metalloproteinase-2 and tissue inhibitor of metallo-proteinase-2 in colorectal carcinoma invasion and metastasis. World J Gastroenterol. 2005;11:3046-50.
15. Shin JE, Jung SA, Kim SE, et al. Expression of MMP-2, HIF-1alpha and VEGF in colon adenoma and colon cancer. Korean J Gastroenterol. 2007;50:9-18.
16. Jass JR, Sobin LH. WHO International Histological Classification of Tumors. Histological Typing of Intestinal Tumors. New York: Springer-Verlag; 1989.
17. Mroczko B, Szmitkowski M, Okulczyk B. Granulocytecolony stimulating factor (G-CSF) and macrophagecolony stimulating factor (M-CSF) in colorectal cancer patients. Clin Chem Lab Med. 2002;40:351-5.
18. Sato H, Kida Y, Mai M, et al. Expression of genes encoding type IV collagen-degrading metalloproteinases and tissue inhibitors of metalloproteinases in various human tumor cells. Oncogene. 1992;7:77-83.
19. Liabakk NB, Talbot I, Smith RA, Wilkinson K, Balkwill F. Matrix metalloprotease 2 (MMP-2) and matrix metalloprotease 9 (MMP-9) type IV collagenases in colorectal cancer. Cancer Res. 1996;56:190-6.
20. Waas ET, Lomme R-MLM, DeGroot J, Wobbes T, Hendriks T. Tissue levels of active matrix metalloproteinase-2 and -9 in colorectal cancer. Br J Cancer. 2002;86:1876-83.
21. Waas ET, Wobbes T, Lomme RM, DeGroot J, Ruers T, Hendriks T. Matrix metalloproteinase 2 and 9 activity in patients with colorectal cancer liver metastasis. Br J Surg. 2003;90:1556-64.
22. Kim TD, Song KS, Li G, et al. Activity and expression of urokinase-type plasminogen activator and matrix metalloproteinases in human colorectal cancer. BMC Cancer. 2006;6:211-21.
23. Groblewska M, Mroczko B, Wereszczyńska-Siemiatkowska U, et al. Serum interleukin 6 (IL-6) and C-reactive protein (CRP) levels in colorectal adenoma and cancer patients. Clin Chem Lab Med. 2008;46:1423-8.
24. Waas ET, Hendriks T, Lomme RM, Wobbes T. Plasma levels of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 correlate with disease stage and survival in colorectal cancer patients. Dis Colon Rectum. 2005;48:700-10.
25. Oberg A, Höyhtyä M, Tavelin B, Stenling R, Lindmark G. Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer. Anticancer Res. 2000;20:1085-91.
26. Gershtein ES, Korotkova EA, Prorokov VV, Kushlinsky NE. Matrix metalloproteinases 2, 3, 13 and their type 2 tissue inhibitor in tumors and plasma of patients with colorectal cancer. Bull Exp Biol Med. 2008;145:362-6.
27. Larsen MB, Stephens RW, Brünner N, et al. Quantification of tissue inhibitor of metalloproteinases 2 in plasma from healthy donors and cancer patients. Scand J Immunol. 2005;61:449-60.
28. Angenete E, Langenskiöld M, Falk P, Ivarsson ML.Matrix metalloproteinases in rectal mucosa, tumour and plasma: response after preoperative irradiation. Int J Colorectal Dis. 2007;22:667-74.
29. Langenskiöld M, Holmdahl L, Falk P, Ivarsson ML. Increased plasma MMP-2 protein expression in lymph node-positive patients with colorectal cancer. Int J Colorectal Dis. 2005;20:245-52.